ASX Share rice
Mon 17 May 2021 - 10:40:am (Sydney)

CGS Share Price

COGSTATE LTDCGSHealth Care Equipment & Services

CGS Company Information

Name:

Cogstate Limited

Sector:

Healthcare

Industry:

Health Information Services

GIC Industry:

Health Care Technology

GIC Sub Industry:

Health Care Technology

Address:

425 Smith Street Fitzroy VIC Australia 3065

Phone:

61 3 9664 1300

Full Time Employees:

163

CEO, MD & Exec. Director:

Mr. Bradley O'Connor C.A., B.Bus, CA

Founder & Chief Innovation Officer:

Prof. Paul Maruff

Gen. Counsel:

Mr. John Glueck B.A., J.D.

Chief Commercial Officer:

Mr. Kenneth Billard

Chief Financial Officer:

Mr. Darren Watson

Chief Technology Officer:

Mr. Benjamin Bloomfield

Chief Science Officer:

Dr. Chris Edgar Ph.D.

VP of Strategic Initiatives, Communication & People:

Ms. Rachel Colite

Financial Controller:

Mr. Keith Hawkins CPA

Company Sec.:

Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.

Company Overview:

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2020, it had participated in approximately 1,800 academic research studies in approximately 200 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is based in Fitzroy, Australia.

CGS Share Price Information

Shares Issued:

170.99M

Market Capitalisation:

$143.63M

Revenue (TTM):

$28.82M

Revenue Per Share (TTM):

$0.18

Earnings per Share:

$0.008

Profit Margin:

0.0339

Operating Margin (TTM):

$0.07

Return On Assets (TTM):

$0.03

Return On Equity (TTM):

$0.06

Quarterly Revenue Growth (YOY):

0.589

Gross Profit(TTM):

$10.10M

Diluted Earnings Per Share (TTM):

$0.008

CGS CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-4,121,034.53

Change To Liabilities:

$-228,233

Total Cashflow From Investing Activities:

$-2,828,266

Net Borrowings:

$1.65M

Net Income:

$-1,315,796

Total Cash From Operating Activities:

$730.21K

Depreciation:

$1.38M

Other Cashflow From Investing Activities:

$308.24K

Change To Account Receivables:

$-4,290

Sale Purchase Of Stock:

$7.69M

Capital Expenditures:

$510.10K

CGS Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-2,079,180

Net Income:

$-1,315,800

Gross Profit:

$10.11M

Operating Income:

$-2,079,180

Interest Expense:

$234.41K

Income Tax Expense:

$-763,382

Total Revenue:

$23.70M

Cost Of Revenue:

$13.59M

CGS Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$6.95M

Total Liabilities:

$15.52M

Total Stockholder Equity:

$16.13M

Other Current Liabilities:

$3.08M

Total Assets:

$31.64M

Common Stock:

$33.04M

Other Current Assets:

$1.14M

Retained Earnings:

$-15,605,249

Other Liabilities:

$635.51K

Other Assets:

$4.98M

Cash:

$15.05M

Total Current Liabilities:

$13.14M

Short-Term Debt:

$2.53M

Property - Plant & Equipment:

$3.61M

Net Tangible Assets:

$9.18M

Total Current Assets:

$16.11M

Net Receivables:

$5.13M

Short-Term Investments:

$22.64M

Accounts Payable:

$1.24M

Short-Term Investments:

$22.64

Non Current Liabilities Total:

$3.47M

CGS Share Price History

CGS News

09 May, 2021
A look at the shareholders of Cogstate Limited ( ASX:CGS ) can tell us which group is most powerful. Institutions often...
03 Apr, 2021
It is hard to get excited after looking at Cogstate's (ASX:CGS) recent performance, when its stock has declined 18...
26 Feb, 2021
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
17 Jan, 2021
Brad O'Connor became the CEO of Cogstate Limited ( ASX:CGS ) in 2005, and we think it's a good time to look at the...
07 Dec, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Innovation Virtual lnvestor Conference are now available for on-demand viewing.
30 Nov, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Innovation lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, December 3rd with the first live webcast at 9:00 AM ET.
17 Nov, 2020
A look at the shareholders of Cogstate Limited (ASX:CGS) can tell us which group is most powerful. Institutions often...
10 Oct, 2020
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
09 Sep, 2020
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Cogstate Ltd. (ASX: CGS; OTCQX: COGZF), a cognitive science and technology company publicly listed on the Australian Securities Exchange, has qualified to trade on the OTCQX® Best Market. Cogstate Ltd. upgraded to OTCQX from the Pink® market.
11 Aug, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...